CARDIOPROGRESS
Foundation for the advancement of cardiology

Cardioprogress Newsletter Dear Colleagues!
The Cardioprogress Foundation resumes publishing a quarterly newsletter dedicated to scientific news in cardiology. If you are interested in specific topics and details of scientific discoveries in the field of cardiology, please write to us. (The e-mail address is indicated on the last page of the newsletter).

Baxdrostat: A “Game Changer” for Hypertension? A new class of antihypertensive agent that blocks the production of aldosterone — a key hormone believed to drive increased blood pressure — has shown impressive results in one of the first pivotal phase 3 trials in patients with resistant or uncontrolled hypertension.

Ross Procedure Making a Comeback in Aortic Valve Disease The Ross procedure, which can be used to treat young people with severe aortic valve disease, has seen wide swings in popularity over the years, but now, with consistent data on long-term survival and valve durability, numbers are steadily climbing again.

AHA Advisory Endorses Endovascular Thrombectomy for Large Core Ischemic Stroke Results of six recent trials of endovascular thrombectomy (EVT) for patients with large-core ischemic stroke (LCIS) provide strong evidence for the benefit of this intervention compared with medical management (MM), a new Science Advisory from the American Heart Association (AHA) has concluded.

AI-Enhanced ECG Predicts Hypertension, Related Risks An artificial intelligence–ECG risk estimation model designed to predict incident hypertension (AIRE-HTN) identifies cases and stratifies the risk for adverse outcomes in addition to traditional markers.

CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards The American Diabetes Association (ADA)’s Standards of Care — 2025 offer new guidance on broader use of continuous glucose monitoring (CGM), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) beyond weight loss, management of metabolic dysfunction-associated liver disease (MAFLD), plus a strong endorsement for drinking water and much more.

ADA Advises Against Using Compounded GLP-1 RA Medications In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.

New Trial Result Pushes Past Antiarrhythmic Therapy After MI For ventricular tachycardia after myocardial infarction, outcomes are better with upfront catheter ablation than drug therapy, which is typically used first, the multinational VANISH2 trial shows.

New Pill Successfully Lowers Lp(a) Levels Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show.

The results of the 35th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology 2024 The anniversary 35th International Congress of Cardiology "Great Wall" and the Asian Congress of Cardiology were held in Beijing at the National Exhibition Center on November 7-10, 2024. As part of the four-day congress, 415 scientific sessions were organized and 2177 reports were made on various areas of cardiology. The congress was attended by 23,980 national and international experts, professors and specialists from almost 40 countries from all the continents of the world.